ClinicalTrials.gg
CompletedNCT02796170Updated Nov 1, 2022Results posted

Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes

A Phase 4 interventional study of Dapagliflozin and Placebo in Type 2 Diabetes and Hypertension, sponsored by Tulane University School of Medicine. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-01.

Sponsored by Tulane University School of Medicine · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Enrollment
173rd of 180
11 · median 82
Started
2016
with 18 others
Phase 4
77 of 180
7 open now
Registered
82nd of 180
by date

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 173rd largest by enrollment, is one of 19 that started in 2016, is one of 77 in phase 4, and was the 82nd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To assess the effect of sodium-glucose cotransporter 2 (SGLT-2) inhibitors on blood pressure and urinary angiotensinogen. This is a cross over study design, where 40 subjects will receive Dapagliflozin for 6 weeks followed by placebo for 6 weeks, or placebo for 6 weeks followed by Dapagliflozin for 6 weeks. In addition there will be an arm of 10 subjects who will receive sulfonylurea in an open label as a comparative to the cross over subjects to assess if the effect of Dapagliflozin may also be in part due to improved glycemic control.

Read the detailed description

Clinical trials of two SGLT2 inhibitors, canagliflozin and dapagliflozin, have reported drops in systolic blood pressure of \~5 mmHg. Inappropriate activation of intrarenal renin-angiotensin system (RAS) is a major contributor to the increased arterial pressure and tissue injury including diabetic nephropathy. A key factor in the intrarenal RAS activation is stimulation of intrarenal angiotensinogen (AGT) which is the precursor of angiotensin peptides. From previous studies, it has been shown that high blood sugars in patients with type1 and type 2 diabetes mellitus is accompanied by elevated intrarenal AGT and urinary AGT levels. High glucose results in stimulation of AGT production. The high glucose levels augments intrarenal AGT levels in diabetes mellitus leading to the development of high blood pressure and diabetic nephropathy.

The investigators propose to conduct a single-center randomized, double blind, cross over study of the effect of Dapagliflozin over 6 weeks, followed by placebo over 6 weeks on the other treatment allocation (those getting placebo first will cross over to Dapagliflozin and vice versa). Treatment will be stratified according to the underlying presence or absence of hypertension.

  1. Type 2 diabetes with hypertension and on renin-angiotensin-aldosterone system (RAAS) blocking drugs with stable blood pressure on therapy; n= 20
  2. Type 2 diabetes without hypertension and not on RAAS blocking drugs n=10

If unable to recruit 10 participants without hypertension the investigators will increase the number with hypertension for a total of 30. Stratification by hypertension status will remain and is important in understanding the effect of SGLT2 inhibition in patients not on BP lowering drugs.

In addition a Sulfonylurea (SU) arm will also be included - 10 participants who are on metformin and other background therapy (with the exclusion of SGLT-2 inhibitor and sulfonylurea) will be recruited. This will be an open-labeled arm. Participants will assessed at baseline. Participants will then receive usual care for 6 weeks. At the end of 6 weeks, participants will then undergo another assessment before being provided SU for 6 weeks. At the end of 6 weeks, participants will undergo assessment again. The aim is to determine whether any effects seen with Dapagliflozin are specific to that drug or related simply to improved glycemic control.

03

Conditions studied

  • Type 2 Diabetes
  • Hypertension

Keywords

  • SGLT-2 inhibitor
  • urinary angiotensinogen
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes with hypertension and on RAAS blocking drugs OR
  • Type 2 diabetes without hypertension and not on RAAS blocking drugs
  • between 7% and 9% (inclusive)
  • Estimated (eGFR) ≥60 ml/min
  • Capacity to understand and sign

Exclusion criteria

Exclusion Criteria:

  • Severe hepatic insufficiency and/or significant abnormal liver function defined as (AST) and/or alanine aminotransferase (ALT) >3x (ULN)
  • Total >2.0 mg/dL
  • Positive serologic evidence of current infectious liver disease, including viral antibody immunoglobulin M (IGM), Hepatitis B surface antigen, and virus antibody
  • Estimated (eGFR) \<60 ml/min
  • Recent cardiovascular events with the last 2 months: acute coronary syndrome (ACS), hospitalization for unstable angina or acute myocardial infarction, acute stroke or (TIA), or post coronary artery revascularization
  • Congestive Heart Failure defined as (NYHA) class IV, unstable or acute congestive heart failure
  • Pregnant or breastfeeding patients
  • Patients who, in the judgement of the investigator, may be at risk for dehydration
  • Blood pressure at enrollment: Systolic ≥165 mmHg and/or Diastolic ≥110 mmHg; At randomization: Systolic ≥160 mmHg and/or Diastolic ≥100 mmHg
  • Use of SGLT-2 inhibitor class drugs is an exclusion for all patients. For patients in the sulfonylurea arm, use of sulfonylurea class drugs is an exclusion.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
11 participants (actual)

Study arms

  • Active comparator
    Dapagliflozin

    Participants underwent 6 weeks of Dapagliflozin or placebo (washout period for 2 weeks) and then crossed over to 6 weeks of placebo or Dapagliflozin.

    Drug: Dapagliflozin · Drug: Placebo

  • Active comparator
    Placebo

    Participants underwent 6 weeks of Dapagliflozin or placebo (washout period for 2 weeks) and then crossed over to 6 weeks of placebo or Dapagliflozin.

    Drug: Dapagliflozin · Drug: Placebo

Interventions

  • 5mg pill taken once daily

  • DrugPlacebo

    5mg pill taken once daily- placebo of Dapagliflozin

06

What researchers measure

Primary outcomes

  1. Change in Blood Pressure From Baseline to 6 Weeks Measured by ABPM

    Blood pressure was measured at baseline with a 24 hour ambulatory blood pressure machine (ABPM), and again after 6 weeks of treatment.

    Time frame: Baseline to 6 weeks

Secondary outcomes

  1. Change in Urinary AGT Levels From Baseline to 6 Weeks

    Urinary Angiotensinogen (AGT) was measured through the collection of 24 hour urine at baseline and again after 6 weeks of treatment. Angiotensinogen was normalized to creatinine.

    Time frame: Baseline to 6 weeks

07

Results

Posted Nov 1, 2022

Participant flow

Participant flow — Overall Study
MilestoneDapagliflozin First Then PlaceboPlacebo First Then Dapagliflozin
Started83
Completed53
Not completed30
Withdrew: Lost to follow-up30

Outcome measures

PrimaryChange in Blood Pressure From Baseline to 6 Weeks Measured by ABPM

Blood pressure was measured at baseline with a 24 hour ambulatory blood pressure machine (ABPM), and again after 6 weeks of treatment.

Time frame:
Baseline to 6 weeks
Reported as:
Mean · mmHg
Change in Blood Pressure From Baseline to 6 Weeks Measured by ABPM
mmHgDapagliflozinPlacebo
Systolic Blood pressure-10.72 ± 6.171.94 ± 17.01
Diastolic blood pressure-3.34 ± 4.21.56 ± 15.05
SecondaryChange in Urinary AGT Levels From Baseline to 6 Weeks

Urinary Angiotensinogen (AGT) was measured through the collection of 24 hour urine at baseline and again after 6 weeks of treatment. Angiotensinogen was normalized to creatinine.

Time frame:
Baseline to 6 weeks
Reported as:
Mean · ng/mg
Change in Urinary AGT Levels From Baseline to 6 Weeks
ng/mgDapagliflozinPlacebo
Change in Urinary AGT Levels From Baseline to 6 Weeks53.85 ± 98.7939.69 ± 58.37

Adverse events

Collected over Each participant was assessed for adverse events in the duration of 16 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapagliflozin0/8 (0%)0/8 (0%)0/8 (0%)
Placebo0/3 (0%)0/3 (0%)0/3 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Dapagliflozin First Then PlaceboPlacebo First Then DapagliflozinTotal
<=18 years000
Between 18 and 65 years7310
>=65 years101
Age, Continuous
Age, Continuous(Years)Dapagliflozin First Then PlaceboPlacebo First Then DapagliflozinTotal
Mean56.5 ± 7.852.7 ± 6.755.5 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)Dapagliflozin First Then PlaceboPlacebo First Then DapagliflozinTotal
Female718
Male123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dapagliflozin First Then PlaceboPlacebo First Then DapagliflozinTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American426
White303
More than one race011
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Dapagliflozin First Then PlaceboPlacebo First Then DapagliflozinTotal
United States8311
Weight
Weight(Kg)Dapagliflozin First Then PlaceboPlacebo First Then DapagliflozinTotal
Mean89.3 ± 17.6114.5 ± 14.996.2 ± 20.0
BMI
BMI(Kg/m^2)Dapagliflozin First Then PlaceboPlacebo First Then DapagliflozinTotal
Mean32.6 ± 7.438.2 ± 8.434.1 ± 7.7
HbA1c
HbA1c(HbA1c %)Dapagliflozin First Then PlaceboPlacebo First Then DapagliflozinTotal
Mean8.0 ± 1.37.9 ± 0.88.0 ± 1.1

17 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Tulane University
    New Orleans, Louisiana 70112, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Aug 2019, 41 months.

Results were first posted in Nov 2022, 3 years 3 months after primary completion. A results delay was requested in Feb 2021.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's 41 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2016
First posted
Jun 10, 2016
StartActual
Mar 2016
Primary completionActual
Aug 2019
CompletionActual
Aug 2020
Results delay requested
Feb 1, 2021
Results first posted
Nov 1, 2022
Last update
Nov 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02796170
Lead sponsor
Tulane University School of Medicine
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Jun 10, 2016
Start date
Mar 2016
Primary completion
Aug 2019
Completion
Aug 2020
Results posted
Nov 1, 2022
Last update
Nov 1, 2022

Study contacts

Dragana Lovre, MD
principal investigator · Tulane University School of Medicine
Tina Thethi, MD
principal investigator · AdventHealth

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion